RCT Comparing Methadone and Buprenorphine in Pregnant Women

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Hendree E. Jones, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00271219
First received: December 28, 2005
Last updated: July 30, 2015
Last verified: July 2015
Results First Received: March 11, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Conditions: Opioid Related Disorders
Pregnancy
Opioid Dependence
Interventions: Drug: Methadone
Drug: Buprenorphine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
1074 Patients were screened for eligibility. 175 underwent randomization. 86 were assigned to receive buprenorphine. 58 of the patients assigned to buprenorphine completed the study. 89 were assigned to receive methadone. 73 of the patients assigned to methadone completed the study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of the 1074 screened: 243 did not give consent. 656 were excluded for a variety of reasons ranging from an estimated gestation age outside the range, to impending legal issues, to multiple-fetus pregnancy.

Reporting Groups
  Description
Methadone

Methadone

Methadone : daily oral dosing 20-140 mg

Buprenorphine

Buprenorphine

Buprenorphine : sl daily 2-32 mg


Participant Flow:   Overall Study
    Methadone     Buprenorphine  
STARTED     89     86  
COMPLETED     73     58  
NOT COMPLETED     16     28  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Methadone

Methadone

Methadone : daily oral dosing 20-140 mg

Buprenorphine

Buprenorphine

Buprenorphine : sl daily 2-32 mg

Total Total of all reporting groups

Baseline Measures
    Methadone     Buprenorphine     Total  
Number of Participants  
[units: participants]
  73     58     131  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     73     58     131  
>=65 years     0     0     0  
Age  
[units: years]
Mean (Standard Deviation)
  27.7  (0.7)     25.3  (0.7)     26.5  (0.7)  
Gender  
[units: participants]
     
Female     73     58     131  
Male     0     0     0  
Region of Enrollment  
[units: participants]
     
United States     54     40     94  
Austria     19     18     37  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Child's Head Circumference Measurement (Measured at Birth)   [ Time Frame: birth ]

2.  Primary:   Child's Length of Hospital Stay   [ Time Frame: delivery until hospital discharge (min=2 days, max=79 days) ]

3.  Primary:   Number of Children Requiring Treatment for Neonatal Abstinence Signs (NAS)   [ Time Frame: From birth until hospital discharge (min=4 days, max=10, depending on site) ]

4.  Primary:   Child's Peak Daily Total NAS Score   [ Time Frame: minimum twice daily from birth until NAS no longer measured (min=10 days) ]

5.  Primary:   Total Amount of Morphine Sulfate That a Neonate Receives to Treat NAS   [ Time Frame: Start of NAS treatment until discontinuation of NAS treatment (min=0 days, max=76 days) ]

6.  Secondary:   Mother's Self-report of Drug Use (Measured Monthly by Time Line Follow Back)   [ Time Frame: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days) ]

7.  Secondary:   Mother's HIV Risk Behaviors (Measured Monthly by Risk Behavior Assessment)   [ Time Frame: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days) ]

8.  Secondary:   Mother's Measures of Dose Adequacy and Acceptance Over Time (Measured Weekly by Dose Adequacy Measure)   [ Time Frame: from study entry until discontinuation or delivery (min=29 days, max=239 days) ]

9.  Secondary:   Mother's Psychosocial Functioning at Delivery as Measured by the Addiction Severity Index Psychosocial Index Score   [ Time Frame: at delivery ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Hendree Jones
Organization: Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, Johns Hopkins University School of Medicine
phone: 919-485-2664
e-mail: hjones18@jhmi.edu


No publications provided by Johns Hopkins University

Publications automatically indexed to this study:


Responsible Party: Hendree E. Jones, Johns Hopkins University
ClinicalTrials.gov Identifier: NCT00271219     History of Changes
Other Study ID Numbers: R01DA15764-1, R01DA015764, R01DA15764-1, DPMC
Study First Received: December 28, 2005
Results First Received: March 11, 2013
Last Updated: July 30, 2015
Health Authority: United States: Food and Drug Administration